drugset / Trial / NCT00010309

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

NCT00010309

Phase 1/2 Unknown Genzyme, a Sanofi Company
Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage II, stage III, or stage IV melanoma.

Timeline

Start
2000-11
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad2/MART-1v2 Vaccine
Subject gp100 antigen Peptide Other

Indications